Comment
Author: Admin | 2025-04-28
Moxifloxacin both increase QTc interval. Modify Therapy/Monitor Closely.nabumetonefluvoxamine, nabumetone.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding SSRIs inhib. serotonin uptake by platelets.naldemedinefluvoxamine will increase the level or effect of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for potential adverse effectsnaproxenfluvoxamine, naproxen.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.naratriptanfluvoxamine and naratriptan both increase serotonin levels. Modify Therapy/Monitor Closely.nateglinidefluvoxamine will increase the level or effect of nateglinide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.nelfinavirfluvoxamine will increase the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nicardipinefluvoxamine will increase the level or effect of nicardipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nifedipinefluvoxamine will increase the level or effect of nifedipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nilotinibfluvoxamine will increase the level or effect of nilotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nimodipinefluvoxamine will increase the level or effect of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nisoldipinefluvoxamine will increase the level or effect of nisoldipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.nitrendipinefluvoxamine will increase the level or effect of nitrendipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.norgestrelfluvoxamine will increase the level or effect of norgestrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong or moderate CYP3A4 inhibitors may increase systemic concentration of norgestrel, which may increase risk for adverse effects nortriptylinefluvoxamine and nortriptyline both increase QTc interval. Modify Therapy/Monitor Closely.octreotidefluvoxamine and octreotide both increase QTc interval. Modify Therapy/Monitor Closely.octreotide (Antidote)fluvoxamine and octreotide (Antidote) both increase QTc interval. Modify Therapy/Monitor Closely.ofloxacinfluvoxamine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.olanzapine/samidorphanfluvoxamine will increase the level or effect of olanzapine/samidorphan by affecting hepatic enzyme CYP1A2 metabolism. Modify
Add Comment